See the DrugPatentWatch profile for eribulin
When does Havlen (eribulin mesylate) lose US patent protection?
I don’t have enough information in the provided materials to state a specific US patent expiry date for Havlen (eribulin mesylate). Patent expiry depends on the exact US patent numbers and which form of protection you mean (basic utility patent term, patent term adjustments, pediatric exclusivity, or any separate extension), and those details weren’t included.
Which patents control eribulin (Havlen) in the US?
To determine the correct expiry date for eribulin mesylate (Havlen) in the US, you need the relevant US patent identifiers (or at least the NDA/label-holder you’re using as the starting point). With that, you can check:
- the expiration date for each listed US patent tied to the drug
- any patent term adjustment (PTA) that can extend a term
- any pediatric exclusivity that can add time
- whether the expiry you want is for a “compound,” “formulation,” or “method” patent
What you can do next to get the exact expiry date
If you share either of the following, I can give you a precise expiry date once the patent records are matchable:
- the US NDA number (or the FDA application number) for Havlen eribulin mesylate, or
- the US patent number(s) listed for Havlen/eribulin mesylate (including any “Orange Book” listed patents)
Quick check: what source typically lists the dates?
The standard place to find US-listed patent expiry information for a specific drug product is the FDA’s Orange Book (Drug Products with Therapeutic Equivalence Evaluations). That database links drug products to the exact US patents and their listed expiration dates.
---
If you paste the Havlen eribulin mesylate NDA number or any Orange Book patent numbers you’re looking at, I’ll translate that into the specific US patent expiry date(s).